Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.

Authors :: Deleuran M
Marcoux D
Bruin-Weller MS
Irvine AD
Baselga E
Ahn K
Castro AP
Bansal A
Chao J
Bégo-Le-Bagousse G
Rossi AB
Source :: Acta dermato-venereologica [Acta Derm Venereol] 2021 Jul 15; Vol. 101 (7), pp. adv00504. Date of Electronic Publication: 2021 Jul 15.
Publication Year :: 2021

Subjects :: Adolescent
Antibodies, Monoclonal, Humanized
Double-Blind Method
Humans
Immunosuppressive Agents adverse effects
Severity of Illness Index
Treatment Outcome
Dermatitis, Atopic diagnosis
Dermatitis, Atopic drug therapy
Eczema

Full Text Access

Tools